Kijimicin
Kijimicin is a polyether ionophore antibiotic originally discovered in Actinomadura sp. MI215-NF3. inhibits HIV-1 replication and reduces the infectivity of progeny viral particles. Kijimicin exhibits inhibitory activity against intracellular T. gondii (IC50 = 45.6 nM), extracellular parasites (IC50 = 216.6 pM) and C. parvum (IC50 = 7.7 nM), and controls acute T. gondii infection in mice. Kijimicin can be used for research on HIV, toxoplasmosis, cryptosporidiosis, and bacterial infections.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 129297-22-9
- Formule: C37H64O11
- Masse moléculaire:684.90
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Antibiotic
MoreVoir tous les produits spécifiques à Isoform Parasite
More
Activité biologique
Description
IC50 & Target
[1]|
HIV-1 2.2 μg/mL (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HFF | IC50 |
46.5 μM
|
Exhibits low cytotoxicity against HFF cells.
Exhibits low cytotoxicity against HFF cells.
|
books/R100000039-I11123919 |
| HCT-8 | CC50 |
> 20 μM
|
Shows no significant cytotoxicity in HCT-8.
Shows no significant cytotoxicity in HCT-8.
|
42075832 |
In Vitro
Kijimicin (7 days) inhibits HIV-1 replication in acutely infected H9 cells with an IC50 of 2.2 μg/mL, and shows little cytotoxicity (IC50 = 88 μg/mL)[1].
Kijimicin (0.1-1000 μg/mL; 72 h) inhibits HIV-1 replication in chronically infected U937 cells[1].
Kijimicin (0.01, 0.1, 1.0 μg/mL; 7 days) reduces the infectivity of progeny HIV-1 viral particles from H9 cells by more than 1 log[1].
Kijimicin exhibits antimicrobial activity against Gram-positive bacteria including Staphylococcus aureus FDA 209P (MIC < 0.78 μg/mL), Bacillus cereus ATCC 10702 (MIC < 0.78 μg/mL), and Micrococcus luteus PCI 1001 (MIC < 0.78 μg/mL)[2].
Kijimicin (7.7 nM; 48 h) inhibits C. parvum growth in HCT-8 cells with an IC50 of 7.7 nM and a CC50 > 20 μM (selectivity index = 2585)[3].
Kijimicin (1-300 nM; 72 h) inhibits intracellular T. gondii RH-GFP growth in HFF cells with an IC50 of 45.6 nM and a selectivity index of 1019.7[4].
Kijimicin (1-2000 pM; 1 h) inhibits extracellular T. gondii RH-GFP invasion into Vero cells with an IC50 of 216.6 pM and a selectivity index of 214,681.4[4].
Kijimicin (50 nM; 24 h) induces morphological changes in T. gondii tachyzoites, including cell swelling and multiple intracellular vacuole-like structures[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HFF cells
-
Concentration:100 nM to 300 μM
-
Incubation Time:72 h
-
Result:Showed an IC50 of 46.5 μM.
-
Cell Line:HFF cells infected with T. gondii RH-GFP
-
Concentration:1, 3, 10, 30, 100, 300 nM
-
Incubation Time:72 h
-
Result:Inhibited intracellular T. gondii growth with IC50 of 45.6 nM and SI of 1019.7.
-
Cell Line:Vero cells
-
Concentration:1, 3, 10, 30, 100, 300, 1000, 2000 pM
-
Incubation Time:1 h pretreatment + 24 h post-infection
-
Result:Inhibited T. gondii invasion into Vero cells with IC50 of 216.6 pM and SI of 214,681.4.
-
Cell Line:Vero cells infected with T. gondii RH-GFP
-
Concentration:50 nM
-
Incubation Time:24 h
-
Result:Induced morphological changes in tachyzoites including cell swelling and vacuole-like structures.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:T. gondii PLK-GFP-infected female BALB/c mice (6-8 weeks old)[4]
-
Dosage:3, 10 mg/kg
-
Administration:i.p.; once daily for 7 days
-
Result:Improved survival rate (91.7%) and reduced clinical signs from 7 to 17 days post-infection(10 mg/kg).
Improved survival rate (66.7%) and reduced clinical signs.
Chemical Information
-
CAS No. 129297-22-9
-
Masse moléculaire 684.90
-
Formule C37H64O11
-
SMILES
C[C@H](C([C@H](C)[C@@H](OC)[C@H]1C)O[C@]21CC[C@@H]([C@H]3CC[C@@](O3)([C@@H]4O[C@@H]([C@@]5(O)O[C@](C[C@@H]5C)(C)[C@H](O)CC)C[C@@H]4C)C)O2)[C@@H](OC)[C@H](C)C(O)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Pureté et documentation
Références
[1]. Yamauchi T, et al. Mechanistic effects of kijimicin on inhibition of human immunodeficiency virus replication. Mol Cell Biochem. 1993 Feb 17;119(1-2):35-41. [Content Brief]
[2]. Takahashi Y, et al. Kijimicin, a polyether antibiotic. J Antibiot (Tokyo). 1990 Apr;43(4):441-3. [Content Brief]
[3]. Kubota R, et al. Development of a Luciferase-Based In Vitro Assay to Evaluate the Efficacy of Anti-Cryptosporidial Drugs Against Cryptosporidium parvum. Pharmaceuticals (Basel). 2026 Apr 3;19(4):576. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Kijimicin Related Classifications
HY-123444 Related Classifications
Powered by Bioz
Keywords
- Kijimicin
- 129297-22-9
- Antibiotic
- HIV
- Reverse Transcriptase
- Parasite
- Bacterial
- polyether ionophore
- antibiotic
- HIV-1
- antiviral
- anti-HIV
- reverse transcriptase
- Toxoplasma gondii
- anti-Toxoplasma
- Cryptosporidium parvum
- anti-Cryptosporidium
- Apicomplexa
- antiparasitic
- anticoccidial
- Eimeria tenella
- Actinomadura
- Inhibitor
- inhibitor
- inhibit